TDC
PGNX

Thompson Davis & Co’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Thompson Davis & Co’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-5,000
Closed -$26K – 1308
2014
Q3 		$26K Hold
5,000
– – 0.03% 407
2014
Q2 		$22K Hold
5,000
– – 0.03% 379
2014
Q1 		$21K Buy
+5,000
New +$25.6K 0.03% 378

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Thompson Davis & Co's PGNX Position: Q4 2014 in Review

Thompson Davis & Co sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2014, closing a stake of 5,000 shares — an estimated $26K sold.

Thompson Davis & Co first reported a position in PGNX in Q1 2014 and held it in 3 quarters. The position peaked at $26K in Q3 2014. 100 funds tracked by Wall St. Rank hold PGNX as of Q4 2014.

  • Thompson Davis & Co reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2014 after selling out during the quarter.
  • Thompson Davis & Co sold 5,000 Progenics Pharmaceuticals Inc shares in Q4 2014, an estimated $26K.
  • Thompson Davis & Co first reported a position in Progenics Pharmaceuticals Inc in Q1 2014 and held it in 3 quarters.
  • Thompson Davis & Co's Progenics Pharmaceuticals Inc position peaked at $26K in Q3 2014.
  • 100 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2014.

Based on Thompson Davis & Co's 13F filing for Q4 2014, filed 6 Feb 2015.